Table 1.

Diabetes-related variables at baseline and during follow-up, and successful glycemic control (unadjusted for baseline variables).

	N (1917)	Mean baseline HbA1c (%) (7.75)	Glycemic control during follow-up
			IP Arm		IS Arm
			N (962)	% with successful control (24.4)	N (955)	% with successful control (35.1)
Baseline DM therapy groups
None	164	6.9	78	24.4	86	45.3
One oral agent	577	7.3	284	29.2	293	57.3
α-glucosidase inhibitor	1	5.2	0	--	1	0.0
Sulfonylurea	316	7.5	154	33.8	162	48.1
Meglitinide	3	7.6	3	33.3	0	--
Biguanide	225	7.0	112	24.1	113	69.0
Thiazolidinedione	32	6.9	15	20.0	17	70.6
Two or more oral agents	652	7.8	327	22.9	325	31.1
Sulfonylurea + biguanide	412	8.0	209	23.0	203	36.0
Sulfonylurea + biguanide + TZD	133	7.6	72	19.4	61	14.8
Other combinations	107	7.6	46	28.3	61	31.1
Insulin alone	205	8.5	117	23.9	88	11.2
Insulin plus oral agent(s)	319	8.3	156	19.2	163	11.0
Ins. + biguanide	106	8.4	52	23.1	54	14.8
Ins. + sulfonylurea + biguanide	60	8.3	25	20.0	35	8.6
Ins. + thiazolidinedione	42	8.2	22	27.3	20	10.0
Ins. + sulfonylurea	39	8.7	25	8.0	14	14.3
Ins. + biguanide + thiazolidinedione	39	8.2	19	10.5	20	5.0
Other combinations	33	7.9	13	23.1	20	10.0
Age at baseline, years
<50	167	8.4	81	11.1	86	31.4
50-55	318	8.2	158	17.1	160	28.1
56-60	380	7.9	191	19.9	189	36.5
61-65	411	7.7	217	22.1	194	33.0
66-70	312	7.4	164	31.1	148	40.5
71+	329	7.2	151	41.1	178	39.3
Duration of diabetes at baseline, years
0-5	759	7.4	370	23.2	389	49.1
6-10	419	7.8	198	23.7	221	33.9
11-15	311	8.2	162	25.3	149	22.8
16-20	221	8.1	111	25.2	110	21.8
21+	207	8.1	121	27.3	86	12.8
HbA1c at baseline
<6.0%	202	--	105	37.1	97	60.8
6.0%-6.5%	295	--	139	30.9	156	50.6
6.6%-7.0%	281	--	147	31.2	134	45.5
7.1%-7.5%	254	--	121	26.4	133	34.6
7.6%-8.0%	221	--	122	21.3	99	28.3
8.1%-8.5%	153	--	80	17.5	73	21.9
8.6%-9.0%	130	--	68	19.1	62	25.8
9.1% +	381	--	180	11.7	201	14.9